Reports Q4 revenue $192.6M, consensus $193.34M. Michael Weiss, CEO, stated, “2025 was a strong year of execution for TG Therapeutics (TGTX), driven by continued momentum for BRIUMVI and meaningful progress across our organization. BRIUMVI delivered significant year-over-year growth in the U.S., supported by increasing adoption and expanding global availability, while we advanced multiple late-stage clinical programs and strengthened our financial position. As we enter 2026, we are focused on building on this foundation. With strong financial guidance, several important clinical milestones ahead, and a disciplined approach to operations, we believe we are well positioned to continue delivering value for patients, healthcare providers, and shareholders.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- TGTX Upcoming Earnings Report: What to Expect?
- TG Therapeutics announces long-term data on Briumvi published in JAMA Neurology
- TG Therapeutics price target lowered to $46 from $49 at JPMorgan
- Buy Rating on Briumvi Driven by Strong Commercial Momentum, 2026 Growth Outlook, and Underappreciated Autoimmune Pipeline Optionality
- TG Therapeutics price target raised to $39 from $37 at Goldman Sachs